Stay updated on Resmetirom Safety and Biomarkers Clinical Trial
Sign up to get notified when there's something new on the Resmetirom Safety and Biomarkers Clinical Trial page.

Latest updates to the Resmetirom Safety and Biomarkers Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now shows a new revision label (v3.6.5) replacing the previous v3.6.4, indicating a deployment-level update to the page.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedUpdated the document revision tag from v3.6.3 to v3.6.4, signaling a newer revision of the page rather than a substantive content change.SummaryDifference0.0%

- Check37 days agoChange DetectedSteatotic Liver Disease was added to the list of related terms on the page, and Fatty Liver Disease was removed. This updates the page's terminology to reflect current disease nomenclature and enhances clarity for readers and indexing.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a small update to the published version. It does not appear to modify visible content.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page’s revision history shows a new version, v3.6.2, replacing the previous v3.6.0, indicating an update to the page’s revision metadata rather than changes to trial details.SummaryDifference0.0%

- Check66 days agoChange DetectedThe study record metadata and indexing keywords, including MeSH terms, sponsor/investigator notes, and location information, have been removed. This changes how the trial is described and found on the site.SummaryDifference17%

Stay in the know with updates to Resmetirom Safety and Biomarkers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom Safety and Biomarkers Clinical Trial page.